लोड हो रहा है...

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

BACKGROUND: The purpose of this retrospective study was to evaluate the survival outcomes of pembrolizumab (PEM) plus enzalutamide (ENZ) versus PEM alone in selected populations of men with previously untreated metastatic castration-resistant prostate cancer (mCRPC) harbouring programmed cell death...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:BMC Cancer
मुख्य लेखकों: Lin, Huanyi, Liu, Qilong, Zeng, Xianshang, Yu, Weiguang, Xu, Guixing
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2021
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045189/
https://ncbi.nlm.nih.gov/pubmed/33849473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08156-1
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!